Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis
Authors' conclusion
Treat-to-target (T2T) goals were similarly met for SLE and RA patients on current treatment.
Study context
- Population
- Outpatients with systemic lupus erythematosus (SLE) and matched seropositive rheumatoid arthritis (RA) with at least three consecutive outpatient visits, August 2021–January 2023392 SLE and 389 RA visits
- Participants
- 100 vs 100
- Exposure
- SLE vs seropositive RA
- SLEn = 100
- RAn = 100reference
- Outcome
- Proportion of patients in remission and LDA
Methodological detailsmatched, outpatient record data
- Matched
- Outpatient record data
Main finding
As reported in the abstract
Remission or LDA (visits)
P = 0.2885
Observational data: associations, not effects.
Further findings
Remission (data points)
P = 0.0018
- Physician global assessment (PhGA) · in remission
- P = 0.0002
- C-reactive protein (CRP) and ESR in active disease · CRP
- P = 0.0107
Physician global assessment (PhGA)
- Not significantly different between SLE and RA in low disease activity (LDA)
- Only slightly higher in SLE in remission
CRP and ESR in active disease
- CRP increased in active RA vs active SLE
- ESR similar in active RA vs active SLE
Original publication
Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis. Rheumatology (Oxford). Published 29 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →